[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611673":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":27,"responsibleParty":41,"collaborators":11,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":11,"maxAge":11,"enrollmentInfo":53,"targetDuration":11,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Showa Inan General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"elderly patients (aged 65 years or older) with active ulcerative colitis","EXPERIMENTAL",null,[13],"Drug: Etrasimod administration",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Etrasimod administration","2 mg of Etrasimod is orally administered everyday.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Norio Saegusa","CONTACT","81265822121","2090","ikyoku.tosho@sihp.jp",[28],{"facility":5,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":11},"RECRUITING","Komagane","Nagano","399-4117","Japan","JP",{"type":36,"coordinates":37},"Point",[38,39],137.93745,35.71657,{"lat":39,"lon":38},{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Akira Horiuchi","Chief of Digestive Disease Center","100611673","efficacy-and-safety-of-etrasimod-in-elderly-patients-with-ulcerative-colitis-100611673",false,"NCT07243639","Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis","A Prospective Study on the Efficacy and Safety of a Novel Oral Drug, Etrasimod, in Elderly Patients With Ulcerative Colitis","Inclusion Criteria:\n\n* Patients with active ulcerative colitis\n\nExclusion Criteria:\n\n* the presence of acute or chronic renal failure, chronic heart disease, pulmonary infection, liver cirrhosis, colorectal cancer, autoimmune disease, and infectious disease","ALL",{"count":54,"type":55},30,"ESTIMATED","INTERVENTIONAL",[58],"NA","Eligible patients will be identified in regular clinical practice. After providing thorough explanation and obtaining voluntary written informed consent, the clinical course, adverse events, endoscopic findings, and histopathological changes in biopsy specimens after Etrasimod administration will be prospectively collected and analyzed.",[61],"Ulcerative Colitis (Disorder)","2025-12-09",{"date":64,"type":65},"2025-12-11","ACTUAL",{"date":67,"type":65},"2025-10-01",{"date":69,"type":55},"2026-09-30",{"name":5,"class":6},1]